The MammaPrint + BluePrint Test Suite
The potential to go even deeper. To treat even more effectively.
With the combined insights of MammaPrint and BluePrint alongside clinical factors, physicians gain a more comprehensive basis for predicting prognosis and the benefit of specific treatments.
MammaPrint enables us to further divide luminal tumors into two subtypes that align with the test’s binary results.